E N D O C A N N A B I N O I D S C I E N C E
E N D O C A N N A B I N O I D S C I E N C E - - PowerPoint PPT Presentation
E N D O C A N N A B I N O I D S C I E N C E - - PowerPoint PPT Presentation
E N D O C A N N A B I N O I D S C I E N C E Disclaimer and cautionary note on forward-looking statements This presentation ("Presentation") contains information about Anandamida Gardens S.A.S. (the
Disclaimer and cautionary note on forward-looking statements
This presentation ("Presentation") contains information about Anandamida Gardens S.A.S. (the "Company", "we", or "our"). Under no circumstances may the content of this Presentation be reproduced, in whole or in part, in any form or forwarded or redistributed to another person. Any forwarding, distribution or reproduction of this document in whole or in part is not authorized.By accepting and reviewing this document, you acknowledge
- least a reasonable standard of care and not use any of the information contained in this document, except to assist you with your evaluation of the Company.
This presentation is for informational purposes only and does not constitute an offer to sell or a request for an offer to purchase Company securities. This presentation is not, and under no circumstances will it be interpreted as a prospectus, offering memorandum, advertisement or public offering of securities. The information in this document has been prepared in order to provide general information to interested parties to assist them in their evaluation of the Company. In this presentation, all dollar values are in American dollars, unless otherwise noted. Certain statements in this Presentation constitute "forward-looking statements" within the meaning of applicable Northamerican securities laws. Forward-looking statements are not historical facts or guarantees of future action. Instead, they are based on our current beliefs, expectations, assumptions, and analyzes made by us regarding the future of our business, future plans and strategies, our operating results, and other future
- the forward-looking statements contained in this presentation on assumptions that we consider reasonable, these forward-looking statements involve risks, uncertainties, and other known and unknown factors that
- and non-recurring items and other special items can be complex and necessarily depends on the particular facts of each of them.
Despite a careful process for preparing and reviewing forward-looking statements, the underlying opinions, estimates and assumptions cannot be guaranteed to be correct. The purpose of the forward-looking statements is to provide the reader with a description of management's expectations regarding our anticipated future performance and may not be appropriate for other purposes. Due to these risks, uncertainties and assumptions, the reader should not place undue reliance on these forward-looking statements. The Company's forward-looking statements are made only as of the date of this presentation, and except as required by
- Market Research and Public Data - This presentation also contains or references certain market, industry, and peer group data that is based on information from independent industry publications, market research,
- third-party sources referenced in this Submission, and therefore the accuracy and completeness of such data is not guaranteed.
- applicable Colombian securities laws, such information is provided to demonstrate the Advance market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and
- additional information and are non-GAAP measures and do not have any standardized meaning prescribed by GAAP. They should not be considered in isolation as a substitute for performance measures prepared under
GAAP and are not necessarily indicative of operating costs presented under GAAP.
About Us
“Clinical Cannabis has become a therapeutic compass to what modern medicine fails to cure”
- Dr. Ethan Russo
Colombian company licensed for cannabis cultivation, research and manufacture of derivatives for medicinal purposes.
What we have done
We have achieved brand recognition in Colombia and Latin America. Our cultivars are registered with the Colombian Agropecuary Institute (ICA) and we are getting ready for commercial production for local and export markets. We have developed cannabinoid formulas rich in terpenoids for the treatment of chronic diseases and we have a broad medical network in Colombia, which we support with continuing education programs.
Anandamide is a neurotransmitter that mimics the effects of compounds present in the cannabis plant, called cannabinoids. Its name derives from the Sanskrit word "ananda" which means inner bliss.
Investment prospects
Global trend
1
2020 2021 2022 2023 2024 2025 2026 2027
North America
Source: Data Bridge Market Research 2020 *CAGR
20%
$30 $40 $50 $60 $70 $80 $90 $100 Billion $USD
Europe Asia South America Middle East and Africa
The global medical cannabis market is expected to account for $ 90.83 billion by 2027.
*CAGR: Compound annual growth rate
Investment prospects
Solid legal framework
2
2016 2017 2018 2019 2020
Colombian Congress enacts Law 1787 that regulates access to medical and
- Decree 613
regulates the production and transformation of medicinal cannabis Decree 1156 regulates the manufacturing, commercialization and sanitary registration for cannabis medications *INVIMA institute issues guide for processing of cannabis magistral preparations
The Colombian Government has developed a robust legislation that
- research, and access to patients.
Decree 315 of 2020 regulates marketing
- containing cannabis
*National Institute for Food and Drug Surveillance
Investment prospects
Competitiveness
and geographical location
3
Low cost production, high standards
- agricultural labor.
16 commercial agreements that support international trade from Colombia. Optimal cultivation variables with 12 hours of sunlight, stable temperatures and
- sustainable and clean
water. Area with wide agro-industrial and exports experience. Production area with high level of security and connectivity, close to José María Córdova International Airport.
COMMERCIAL AGREEMENTAgro-industrial cluster in Eastern Antioquia less than 20 minutes away from Rionegro’s Free Trade Zone, the JMC International Airport, the municipality of Rionegro and 30 minutes away from Medellín through the Oriente Tunnel.
NORTH
Antioquia Rionegro
Our location
CULTIVATION
Psychoactive and non-psychoactive cannabis with high productivity and resistance.
FABRICATION
cGMP laboratory for ethanolic extraction with subcritical CO2 for the recovery of terpenes.
FINISHED PRODUCTS
Magistral formulas, phytotherapeutics, cosmetics, dietary supplements, beverages, veterinary products and others.
COMMERCIALIZATION
Local market and exports to Latam, North America, Europe, Asia and Oceania.
SEEDS
High quality registered plant material.
Our business model
Our milestones and projections
Cannabis-derived manufacturing license License to use cannabis seeds Non-psychoactive cannabis cultivation license Psychoactive cannabis cultivation license Seedling source resolution (106 varieties) Non-psychoactive agronomic evaluation test Approval of psychoactive quotas Psychoactive agronomic evaluation test Greenhouse construction for production Laboratory construction for extraction Beginning of non-psychoactive commercial cultivation
- Beginning of psychoactive commercial cultivation
JUL 22 JUL/OCT JAN 30 MAR/JUL MAY 29 OCT 11 DEC 16 DEC 17 AUG/DEC SEP/DEC OCT JAN MAY
2020 2021 2019
Mother plants greenhouse Agronomic evaluation greenhouse Production greenhouse Extraction lab
- N
ACCESS ROADS PRODUCTION
45 2 . m 1.50m 1 . 5 mS E M I T Ú N E L
2.947 m2OFFICES LAB
7,5m 10,10m 9m 15,5m , 6 m 0,5m 3 , 5 m 2m 7,2m 0,8m 0,8m 0,5m 0,5mPRODUCTION
Our facilities
45 2.00m 1 . 5 m 1.50mSEMITÚNEL
2 . 9 4 7 m 2 MOTHER PLANTS
AGRONOMIC EVALUATIONSTotal area: 4.7 Ha
El Tablazo, Rionegro, Antioquia
Superventilated type Anti thrips mesh enclosure Polyethylene for maximum use
- f solar radiation
Automated drip irrigation system
Total production greenhouse area 2020 10.000 m2 2021 15.000 m2 2022 20.000 m2 2023 30.000 m2 2024 40.000 m2 2025 50.000 m2
Our greenhouses
Contribution Margin COP$MM
- 10.000
20.000 30.000 40.000 50.000 60.000 70.000 2021 2022 2023 2024 2025
Contribution Margin USD$K
Projection of results as for 2021-2025
- 10.000
20.000 30.000 40.000 50.000 60.000 70.000 2021 2023 2024 2025
EBITDA USD$K
2022
- 5.000
10.000 15.000 20.000 25.000 30.000 35.000 40.000 45.000 2021 2022 2023 2024 2025
- USD$K
- 10.000
20.000 30.000 40.000 50.000 60.000 70.000 80.000 90.000 2021 2022 2023 2024 2025
Sales USD$K
CBD
50mg/mL S O L U C I Ó N O R A LProduct development
FULL SPECTRUM PHYTOTHERAPEUTICS AND MAGISTRAL FORMULAS
- O ESTANDARIZADO DE CA
- rios Medick para Anandamida Gardens S.A.S. Rionegro, Antioquia,
1000mL
FULL SPECTRUM STANDARDIZED CANNABIS EXTRACT
30mLCBD/THC
- S O L U C I Ó N O R A L
THC
50mg/mL S O L U C I Ó N O R A LCBD
O ESTANDARIZADO DE CA
- rios Medick para Anandamida Gardens S.A.S. Rionegro, Antioquia,
1000mL
THC
O ESTANDARIZADO DE CA
- rios Medick para Anandamida Gardens S.A.S. Rionegro, Antioquia,
CBD/THC
- CBD Oral solution
Dropper bottle 30mL and 10mL
- 50mg/mL
- THC Oral solution
Dropper bottle 30mL and 10mL
- 50mg/mL
- CBD/THC Oral solution
Dropper bottle 30mL and 10mL
- 50mg/mL
- 50mg/mL
CBD 1000mL Bulk
- THC
1000mL Bulk
- CBD/THC
1000mL Bulk
- 1000mL
Endomedicine is a medical area of focus that deals with prevention, diagnosis and treatment of chronic diseases through modulation
- f the Human Endocannabinoid System (ECS).
2016 First Symposium on Medicinal Cannabis 300 attending physicians and students Faculty of Medicine Universidad del Cauca 2019 International Seminar on Endomedicine 500 health professionals attendees Parque Telemedellín 2020 Endomedicine Webinar 1000 attendees from 29 countries Webinar for health professionals 2020/2021 Endomedicine Course: medicinal cannabis and complementary therapies aimed at health professionals
Medical education programs
endomedicina
endomedicina
CANNABIS · PSICODÉLICOS · TERAPIAS COMPLEMENTARIASW E B I N A R
medicina
endo
II SEMINARIO DE
2019 2020
Company Ticker *Market Cap
*CDN$ (as of July 24 - 2020)
Pharmacielo Khiron Life Sciences Avicanna Blueberries Medical Medcolcanna PCLO KHRN AVCN BBN MCCN 73.84M 59.21M 36.43M 4.54M 7.68M
Main cannabis companies in Colombia
www.unicauca.edu.co www.grupocurativa.com www.analdex.org www.fundaciondaya.org www.tni.org www.empirialabs.com www.endomedicina.com
endomedicina
CANNABIS · PSICODÉLICOS · TERAPIAS COMPLEMENTARIASEthan Russo
CERTIFIED NEUROLOGIST Founder of Cannabis Research.org Medical Director at CReDO Science.
Mara Gordon
HEAD OF PROCESS ENGINEER Researcher and Co-founder of Aunt Zelda’s California.
Paola Pineda
SURGEON AND RESEARCHER Medical Director at Grupo Curativa Colombia.
Cristina Sánchez
BIOLOGIST AND RESEARCHER Professor at Universidad Complutense de Madrid.
José Rodríguez Orengo
CHEMIST AND RESEARCHER Professor at the School
- f Medicine University
- f Puerto Rico.
Board of advisors
Strategic allies
Garrett Seale
NEUROSCIENTIST AND RESEARCHER Brown university U.S.A.
www.asocolcanna.org www.cannabisclinicians.org www.labmedick.com www.bancoagrario.gov.co www.alpharma.com.co www.asisfarma.com.co
Diana Paola Valenzuela
LEGAL DIRECTOR
Alexander Gómez
CHIEF OF COMMUNICATIONS
Santiago Bravo
CHIEF OF LOGISTICS
Juliana Hernández
ADMINISTRATIVE LEADER
Zoraida Gutiérrez
OPERATIONAL DIRECTOR
Fáber de Jesús Chica
CHIEF OF CULTIVATION
Adrián López
AGRONOMIST
Lina María Escobar
TECHNICAL DIRECTOR (E)
Jaime Ignacio Gutiérrez
PRESIDENT
Julián Caicedo
MANAGING DIRECTOR
José Joaquín Varela
CHIEF SCIENTIFIC
Freddy Guarín
COMMERCIAL DIRECTOR
Our team
Carrera 48 No. 16 - 30 Medellín, Colombia. Contact: (4) 5 575811 info@anandamidagardens.com Investor relations: Jaime Ignacio Gutierrez jaime.gutierrez@anandamidagardens.com Visit our website: www.anandamidagardens.com Follow us in: